GFM
CHRS icon

GF Fund Management’s Coherus Oncology CHRS Stock Holding History

GF Fund Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.59K Buy
2,714
+413
+18% +$733 ﹤0.01% 610
2025
Q4 		$3.27K Buy
+2,301
New +$3.35K ﹤0.01% 635

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GF Fund Management's CHRS Position: Q1 2026 in Review

GF Fund Management increased its Coherus Oncology (CHRS) stake by 18% in Q1 2026, buying an estimated $733 and bringing the position to 2,714 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

GF Fund Management first reported a position in CHRS in Q4 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • GF Fund Management held 2,714 shares of Coherus Oncology worth $4.59K as of Q1 2026.
  • GF Fund Management bought 413 Coherus Oncology shares in Q1 2026, an estimated $733.
  • Coherus Oncology made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #610 holding.
  • GF Fund Management first reported a position in Coherus Oncology in Q4 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.